Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476931 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
A Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT00476931 is a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Sangamo Therapeutics. The registered enrollment target is 91 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00476931, a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL SB-509
Study Locations (20)
California
- Coordinated Clinical Research - La Jolla
- Advanced Medical Research, LLC - Lakewood
- Torrance Clinical Research - Lomita
- SF Clinical Research Center - San Francisco
- Diablo Clinical Research - Walnut Creek
Florida
- Bradenton Research Center - Bradenton
- Neurology Clinical Research - Sunrise
- Laszlo J. Mate', M.D. - West Palm Beach
New York
- Upstate Clinical Research - Albany
- Peripheral Neuropathy Center, Weill Medical College of Cornell University - New York
- Neurological Institute Columbia University College of Physicians and Surgeons - New York
Texas
- Nerve and Muscle Center of Texas - Houston
- Diabetes Center of the Southwest - Midland
- DGD Research - San Antonio
Kansas
- University of Kansas Medical Center - Kansas City
Nebraska
- Creighton Diabetes Center - Omaha
Nevada
- Advanced Biomedical Research of America - Las Vegas
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476931
The ClinicalTrials.gov registry entry for NCT00476931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00476931 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00476931 about?
NCT00476931 is a clinical study titled "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy". The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
What is the current status of trial NCT00476931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2007-05. Estimated completion is 2010-12.
What conditions does trial NCT00476931 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetic Polyneuropathy.
What interventions are being tested in trial NCT00476931?
The interventions under investigation include: Placebo (OTHER), SB-509 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00476931?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00476931 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.